97270 ⎘
Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation
TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS
#1802SYSTEM AND METHOD FOR FORMING AN INTERLOCKING SOLAR PANEL ARRAY
#1803FcgammaRIIB Fusion Proteins and Compositions Thereof
#1804Method of modulating the activity of functional immune molecules
#1805Engineering Fc antibody regions to confer effector function
#1806Method for immobilizing glycoprotein
#1807Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
#1808Antibody-based therapeutics with enhanced ADCC activity
#1809Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform
#1810Glycosylated specificity exchangers
#1811GLYCOSYLATION ENGINEERED ANTIBODY THERAPY
#1812Methods and vectors for generating asialylated immunoglobulins
#1813STABLE ANTIBODY COMPOSITIONS AND METHODS OF STABILIZING SAME
#1814Therapeutic use of anti-CS1 antibodies
#1815ALTERED BR-3 BINDING POLYPEPTIDES
#1816Variant target binding agents and uses thereof
#1817HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF
#1818Antibody for ADCC And Inducing Cytokine Production
#1819Antibody Composition-Producing Cell
#1820Human antibodies that bind CD22 and uses thereof
#1821Antagonists of IL-6 to prevent or treat thrombosis
#1822Antibodies to IL-6 and use thereof
#1823Optimizing glycan processing in plants
#1824Optimized antibodies that target HM1.24
#1825HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF
#1826Anti-IGF-1R Antibodies and Uses Thereof
#1827Anti-IGR-1R antibodies and uses thereof
#1828Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa
#1829Human cytomegalovirus neutralizing antibodies and use thereof
#1830MUTANT POLYPEPTIDE HAVING EFFECTOR FUNCTION
#1831Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor
#1832SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA 1,6-FUCOSYLTRANSFERASE
#1833Use of human cells of myeloid leukaemia origin for expression of antibodies
#1834Biological products
#1835Monoclonal antibodies against CD30 lacking in fucosyl residues
#1836Methods of Treating Autoimmune Diseases Using CD4 Antibodies
#1837Potency assays for antibody drug substance binding to an Fc receptor
#1838Therapeutic antibodies
#1839Composition comprising antibodies to LINGO or fragments thereof
#1840METHOD FOR REDUCING FUCOSE CONTENTS OF RECOMBINANT PROTEINS
#1841PCSK9 polypeptides
#1842Clearance of abnormal IGA1 in IGA1 deposition diseases
#1843GLYCOSYLATED SPECIFICITY EXCHANGER
#1844Potentiation of Apoptosis by Monoclonal Antibodies
#1845Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
#1846Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
#1847Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
#1848Antagonists of IL-6 to raise albumin and/or lower CRP
#1849Glyco-engineered antibodies
#1850Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
#1851Antibodies to lymphotoxin-alpha
#1852RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY
#1853Methods of identifying anti-inflammatory compounds
#1854Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
#1855Sp35 antibodies and uses thereof
#1856Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
#1857Antibodies against amyloid beta 4 with glycosylation in the variable region
#1858Therapeutic use of anti-CS1 antibodies
#1859Fusion proteins containing recombinant cytotoxic RNAses
#1860Therapeutic use of anti-CS1 antibodies
#1861THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
#1862Cells with altered fucosylation and producing antibodies therefrom
#1863Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
#1864Humanized anti-beta7 antagonists and uses therefor
#1865Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditions
#1866Optimized Fc Variants and methods for their generation
#1867HOST CELL LINES FOR PRODUCTION OF ANTIBODY CONSTANT REGION WITH ENHANCED EFFECTOR FUNCTION
#1868Method of producing antibodies with improved function
#1869Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
#1870Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
#1871Glycoengineered, recombinant antibody
#1872Anti-Aβ globulomer 5F7 antibodies
#1873Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#1874ANTIBODY CHARACTERIZATION TEST
#1875MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES
#1876Production of glycoproteins with reduced O-glycosylation
#1877Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
#1878Treatment of tumors using specific anti-L1 antibody
#1879Immunoglobulin variants and uses thereof
#1880Human C-FMS antigen binding proteins
#1881CD19 antibodies and their uses
#1882Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform
#1883COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR
#1884BIOLOGICAL MATERIALS AND USES THEREOF
#1885METHODS OF USE OF ANTIBODIES WITH REDUCED IMMUNOGENICITY OR TOXICITY
#1886STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM
#1887FcγRIIB specific antibodies and methods of use thereof
#1888Optimized Fc variants and methods for their generation
#1889Optimized Fc variants and methods for their generation
#1890FcγRIIB specific antibodies and methods of use thereof
#1891Human monoclonal antibodies to O8E
#1892Optimized Fc variants and methods for their generation
#1893Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
#1894GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES
#1895Deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
#1896COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES
#1897Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
#1898Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1899Materials and methods for improved immunoglycoproteins
#1900Human monoclonal antibodies to CD70
#1901TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6
#1902Antibodies to IL-6 and use thereof
#1903Conjugate of an antibody against CD4 and antifusogenic peptides
#1904Antibodies to TNF-α and use thereof
#1905Antibodies that bind to a portion of the VWC domain of connective tissue growth factor
#1906Apoptotic anti-IgE antibodies
#1907Antigen binding molecules with increased Fc receptor binding affinity and effector function
#1908Fc Variants Having Decreased Affinity for FcyRIIb
#1909POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS
#1910Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
#1911Method for the mass production of immunoglobulin Fc region deleted initial methionine residues
#1912Antibody or Antibody Fragment Coupled with an Immunogenic Agent
#1913Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
#1914Anti-αβantibodies and uses thereof
#1915Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
#1916Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)
#1917Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#1918Methods of treatment with glycosylated antibodies
#1919ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
#1920Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
#1921SINGLE CHAIN FC, METHODS OF MAKING AND METHODS OF TREATMENT
#1922OPTIMIZED ANTIBODIES THAT TARGET CD19
#1923Fused Protein Composition
#1924Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
#1925Method for Treating CCR4-Related Diseases
#1926Fc variants with optimized Fc receptor binding properties
#1927POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS
#1928METHOD OF TREATMENT OF TH2-MEDIATED CONDITIONS USING OPTIMIZED ANTI-CD30 ANTIBODIES
#1929Method of modulating the activity of functional immune molecules
#1930Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
#1931Fc Variants with Increased Affinity for FcyRIIc
#1932Compositions and methods of tolerizing a primate to an antigen
#1933Fc variants with increased affinity for FcγRIIc
#1934Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#1935Anti-glypican 3 antibody having modified sugar chain
#1936Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#1937Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
#1938Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#1939Method for Obtaining Modified Proteins and Viruses with Intact Native Binding Site
#1940N-glycosylated antibody
#1941Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
#1942IL-5R-specific antibody composition
#1943GLYCOPROTEIN COMPOSITIONS
#1944NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES
#1945Production of glycoproteins
#1946Antigen-binding polypeptides and their uses
#1947Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
#1948MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1949Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants
#1950Fc Variants with Increased Affinity for FcyRIIC
#1951Fc Variants with Increased Affinity for FcyRIIc
#1952NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES
#1953CD16A binding proteins and use for the treatment of immune disorders
#1954Humanized anti-beta7 antagonists and uses therefor
#1955Antibodies against insulin-like growth factor I receptor and uses thereof
#1956Polynucleotides encoding novel PCSK9 variants
#1957Fc Variants Having Decreased Affinity for FcyRl
#1958Methods and Compositions for Antagonism of RAGE
#1959Humanized c-Kit antibody
#1960Methods for Preventing and Treating Amyloidogenic Diseases
#1961LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS
#1962Fc Variants with Increased Affinity for FcyRlla
#1963Fc variants having increased affinity for fcyrllc
#1964Method for selecting CHO cell for production of glycosylated antibodies
#1965CD16A binding proteins and use for the treatment of immune disorders
#1966Anti-IGF-1R antibodies and uses thereof
#1967Fc Variants Having Decreased Affinity for FcyRlla
#1968Fc Variants Having Decreased Affinity for FcyRIIc
#1969Fc Variants Having Decreased Affinity for FcyRllla
#1970Fc Variants Having Increased Affinity for FcyRllla
#1971Fc Variants Having Increased Affinity for FcyRl
#1972Fc variants
#1973Novel lgG3 Antibodies for Stimulating Phagocytosis
#1974Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor
#1975Oligosaccharide modification and labeling of proteins
#1976Methods for modulating mannose content of recombinant proteins
#1977Humanized anti-CD3 specific antibodies
#1978IMMUNOCONJUGATES AND HUMANIZED ANTIBODIES SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS
#1979OPTIMIZED ANTI-CD30 ANTIBODIES
#1980Anti-CD19 antibody composition and method
#1981Method of modulating the activity of functional immune molecules to Her-2
#1982Method of modulating the activity of functional immune molecules to CD52
#1983Method of modulating the activity of functional immune molecules to GM2
#1984Method of modulating the activity of functional immune molecules to CXCR4 protein
#1985Method of modulating the activity of functional immune molecules
#1986Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein
#1987Optimized proteins that target Ep-CAM
#1988Humanized anti-CD3 specific antibodies
#1989Anti-CD19 antibodies with reduced immunogenicity
#1990Optimized anti-CD30 antibodies
#1991Fc Variants With Optimized Fc Receptor Binding Properties
#1992Sugar-chain-altered anti-hm1.24 antibody
#1993Bivalent IgY antibody constructs for diagnostic and therapeutic applications
#1994Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
#1995Humanized anti-CD3 specific antibodies
#1996Optimized proteins that target Ep-CAM
#1997Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
#1998Therapeutic agents for solid tumors
#1999Antibody-based therapeutics with enhanced ADCC activity
#2000Methods of treatment using anti-CD3 antibodies
#2001Plant production of immunoglobulins with reduced fucosylation
#2002Modified antigen binding molecules with altered cell signaling activity
#2003Prokaryotically produced antibodies and uses thereof
#2004Biological products
#2005Antibodies having altered effector function and methods for making the same
#2006Proteolysis resistant antibody preparations
#2007Method of treating autoimmune disease using humanized anti-CD16A antibodies
#2008Prokaryotically produced antibodies and uses thereof
#2009GLYCOPROTEIN COMPOSITIONS
#2010Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
#2011Antibody Composition-Producing Cell
#2012Anti-rhesus D monoclonal antibodies
#2013Antibodies directed against amyloid-beta peptide and nucleic acids encoding same
#2014Factor VIII inhibitory antibodies with reduced glycosylation
#2015Methods for stabilizing proteins
#2016Glycosylated specificity exchangers
#2017Humanized anti-CD3 specific antibodies
#2018Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#2019Compositions and methods for increasing the stability of antibodies
#2020Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
#2021Optimizing glycan processing plants
#2022Single chain antibody with cleavable linker
#2023Glycosylated immunoglobulin and immunoadhesin comprising the same
#2024Antimicrobial composition for local use on mucosal membranes and skin
#2025Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
#2026Glycosylated specificity exchangers
#2027Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#2028Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
#2029Use of ADCC-optimized antibodies for treating low-responder patients
#2030FcgammaRIIB-specific antibodies and methods of use thereof
#2031Humanized anti-CD3 specific antibodies
#2032Humanized anti-CD3 specific antibodies
#2033Humanized anti-CD3 specific antibodies
#2034Antigen-binding polypeptides and their uses
#2035Engineering Fc Antibody regions to confer effector function
#2036Antibody for adcc and inducing cytokine production
#2037Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
#2038Humanized anti-beta7 antagonists and uses therefor
#2039Humanized anti-CD3 specific antibodies
#2040Therapeutic binding molecules
#2041Antibody composition-producing cell
#2042Mammalian host cell modified by RNAi to inhibit α 1,6-fucosyltransferase
#2043Antibody composition-producing cell
#2044Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation
#2045Engineered antibody fragment that irreversibly binds an antigen
#2046Antibodies directed against amyloid-beta peptide and methods using same
#2047Antibodies directed against amyloid-beta peptide
#2048Immunoglobulin variants and uses thereof
#2049Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
#2050Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
#2051Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
#2052Methods for producing antibody compositions with increased ADCC
#2053Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
#2054Immunoglobulin variants and uses thereof
#2055Therapeutic use of anti-CS1 antibodies
#2056Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
#2057Fusion proteins containing recombinant cytotoxic RNAses
#2058Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#2059CCR4-specific antibody composition
#2060Method of modulating the activity of functional immune molecules
#2061Method of modulating the activity of functional immune molecules
#2062Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
#2063Antibody composition-producing cell
#2064Fcgamma-RIIB-specific antibodies and methods of use thereof
#2065Monoclonal antibodies with enhanced ADCC function
#2066Monovalent antibody fragments useful as therapeutics
#2067IL-5R-specific antibody composition
#2068Cells of which genome is modified
#2069Method of stabilizing protein
#2070Prokaryotically produced antibodies and use thereof
#2071Production of functional antibodies in filamentous fungi
#2072Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
#2073Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
#2074Methods of use of antibodies with reduced immunogenicity or toxicity
#2075Modified antibodies stably produced in milk and methods of producing same
#2076Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
#2077Glycosylated specificity exchangers
#2078Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
#2079Therapeutic binding molecules
#2080Enhancing the circulating half-life of interleukin-2 proteins
#2081Polyalkylene oxide-modified single chain polypeptides
#2082Single chain antigen-binding polypeptides for polymer conjugation
#2083Treatment of chronic joint inflammation
#2084Binding agents with differential activity
#2085Therapeutic agent for patients having human FcgammaRIIIa
#2086Therapeutic use of anti-CS1 antibodies
#2087Glycosylated specificity exchangers
#2088Polyalkylene oxide-modified single chain polypeptides
#2089Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
#2090BCMA × CD3 T bispecific cell engager
#2091Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof
#2092Anti-CD20 antibody compositions
#2093Anti-CD20 antibody compositions
#2094Methods for making recombinant proteins
#2095Bispecific anti-HER2 antibody
#2096Methods for modifying glycosylation using manganese
#2097Methods for making recombinant proteins